| Basics |
Novavax, Inc.
Novavax Inc is a clinical-stage vaccine company. It is engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.
|
| IPO Date: |
December 13, 1995 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.2B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.83 | 3.63%
|
| Avg Daily Range (30 D): |
$0.25 | 3.76%
|
| Avg Daily Range (90 D): |
$0.26 | 3.60%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
3.96M |
| Avg Daily Volume (30 D): |
10.47M |
| Avg Daily Volume (90 D): |
6.46M |
| Trade Size |
| Avg Trade Size (Sh.): |
199 |
| Avg Trade Size (Sh.) (30 D): |
183 |
| Avg Trade Size (Sh.) (90 D): |
159 |
| Institutional Trades |
| Total Inst.Trades: |
8,892 |
| Avg Inst. Trade: |
$3.5M |
| Avg Inst. Trade (30 D): |
$1.74M |
| Avg Inst. Trade (90 D): |
$1.91M |
| Avg Inst. Trade Volume: |
.09M |
| Avg Inst. Trades (Per Day): |
4 |
| Market Closing Trades |
| Avg Closing Trade: |
$6.97M |
| Avg Closing Trade (30 D): |
$2.51M |
| Avg Closing Trade (90 D): |
$2.42M |
| Avg Closing Volume: |
223.24K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$3.03
|
$3.22
|
$-.52
|
|
Diluted EPS
|
$2.64
|
$2.93
|
$-.52
|
|
Revenue
|
$ 1.25B
|
$ 666.66M
|
$ 88.31M
|
|
Gross Profit
|
$ 1.1B
|
$ 652.54M
|
$ 51.64M
|
|
Net Income / Loss
|
$ 478.7M
|
$ 518.65M
|
$ -81.03M
|
|
Operating Income / Loss
|
$ 411.41M
|
$ 515.51M
|
$ -131.08M
|
|
Cost of Revenue
|
$ 157.65M
|
$ 14.12M
|
$ 36.67M
|
|
Net Cash Flow
|
$ -217.46M
|
$ -266.81M
|
$ -43.3M
|
|
PE Ratio
|
2.66
|
|
|
| Splits |
|
May 10, 2019:
1:20
|
|
